Fluxion Biosciences to defend against alleged automated patch clamp system patent infringement lawsuit

Fluxion Biosciences, Inc. announced today that a lawsuit alleging patent infringement had been filed against it in the US District Court of Northern California by Cellectricon AB, its competitor in the field of automated ion channel screening systems for drug discovery. Cellectricon has asserted U.S. Patents Nos. 7,390,650, 7,470,518, and 7,563,614 in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros and licensed to Cellectricon. Fluxion believes that the lawsuit is without merit and that Fluxion’s innovative IonFlux™ automated patch clamp system does not infringe the asserted patents. Fluxion intends to defend this lawsuit vigorously.

“Fluxion has invested considerable time and resources to develop its own intellectual property position for cell-based screening systems, and we respect the intellectual property rights of others. Cellectricon’s claim of patent infringement is a baseless attempt to block Fluxion’s penetration and growth in the ion channel screening market.”

Jeff Jensen, Chief Executive Officer of Fluxion, said in response to the lawsuit: "Fluxion has invested considerable time and resources to develop its own intellectual property position for cell-based screening systems, and we respect the intellectual property rights of others. Cellectricon’s claim of patent infringement is a baseless attempt to block Fluxion’s penetration and growth in the ion channel screening market.”

SOURCE Fluxion Biosciences